# A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years

> **NCT04421105** · PHASE1 · COMPLETED · sponsor: **Eleusis Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Lysergic acid diethylamide (LSD) 5µg
- **DRUG:** Lysergic acid diethylamide (LSD) 10µg
- **DRUG:** Lysergic acid diethylamide (LSD)20 µg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04421105
- **Lead sponsor:** Eleusis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-29
- **Primary completion:** 2015-10-30
- **Final completion:** 2015-11-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421105, "A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04421105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*